Can a new MS drug help you walk better and avoid falls?
NCT ID NCT06629428
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether ublituximab, a drug for relapsing multiple sclerosis, can improve walking function and reduce fall risk. Twenty-five participants will receive the drug for 48 weeks, with walking, disability, and thinking tests before, during, and after treatment. They will also be exposed to a simulated slip on a treadmill to see how well they recover.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ublituximab
What this could lead to
If it works, this could show that ublituximab improves walking and reduces falls in people with relapsing MS.
What could go wrong
This is a very small, early-phase study with only 25 participants, so results may not apply to everyone. It is designed to measure walking changes, not to prove long-term disease control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS (MS) - RELAPSING-REMITTING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atlanta Neuroscience Institute
RECRUITINGAtlanta, Georgia, 30327, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Georgia State University
NOT_YET_RECRUITINGAtlanta, Georgia, 30303, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact